Polyrizon shares jump 77.57% intraday after pivotal manufacturing milestone for PL-14 nasal spray.

Polyrizon surged 77.57% intraday on December 4, 2025, driven by two pivotal developments. First, the company announced a manufacturing milestone, successfully producing scalable batches of its PL-14 Allergy Blocker under controlled conditions, validating its Capture & Contain™ hydrogel technology for clinical trials. Second, new preclinical data demonstrated that Polyrizon’s Trap & Target™ naloxone hydrogel exhibited significantly stronger mucoadhesion than a commercial nasal spray, enhancing its potential for emergency opioid overdose reversal.